Novavax COVID-19 vaccine for teens 82% effective

Yahoo Finance's Anjalee Khemlani details Novavax's data on their COVID-19 vaccine for teens, its timeline for filing for emergency use authorization with the FDA, and international vaccine delays from the company.

Video Transcript

EMILY MCCORMICK: We have some breaking news on the vaccine front from Novavax. Yahoo Finance's own health reporter, Anjalee Khemlani, is back with the breakdown. Anjalee, give us the details.

ANJALEE KHEMLANI: Thanks, Emily. Yeah, so we heard that Novavax has results from its adolescent trial for ages 12 to 17, saying that the vaccine is proving 82% effective against the virus, mostly looking at Delta, actually, the trial lasted until just about before Omicron became really prevalent. So they don't have any data on that right now, but they do have pretty strong indications of the vaccine in that group, especially compared to the older age group.

No adverse events or severe adverse events really noted there. No known indications of heart inflammation, which we know has been an occurrence with the mRNA vaccines. So they do plan to file for that emergency use authorization in this quarter, following suit, of course, what we've seen with that 18 and older filing just last month. No update from the FDA filing just yet, but they do have it in place.

Meanwhile, just some updates about the vaccine itself and its shipments around the world. There have been some reports about delays in Europe. The company says that that is a result of local distribution issues, but that is going to be sorted out by the end of the month.

Meanwhile, in South Korea, we're seeing that vaccine roll out next week. They do anticipate that there will be some word, hopefully, from the FDA soon, but nothing yet. And as we recall, this is the fourth vaccine from that initial Operation Warp Speed program. So this is still waiting and pending here in the US. Back to you.